Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07534176 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

To Evaluate the Impact of Smoking on PK After Single-dose Oral Administration of GS1-144 Tablets .

StatusCompleted
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary endpoints: details revised at 3 of 9 entries Show 6 more changesShow less
    • Trial completed
    • Primary completion date changed from estimate of Oct 20, 2026 to Jul 2, 2026
    • Study completion date changed from estimate of Feb 8, 2027 to Jul 29, 2026
    • Eligibility criteria expanded, about 13 words
    • Secondary endpoints: details revised at 1 of 8 entries
    • Site details revised
  2. Recruitment opened
    • Start date changed from estimate of May 27, 2026 to May 20, 2026
    • Site details revised
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A Drug-Drug Interaction Study to Evaluate the Effect of Smoking (CYP1A2 Inducer) on the Pharmacokinetics Following a Single Oral Dose of GS1-144 Tablets in Chinese Healthy Postmenopausal Female Trial Participants
Trial Details
NCT Number NCT07534176
Lead Sponsor Changchun GeneScience Pharmaceutical Co., Ltd.
Conditions
(from sponsor)		 Postmenopause
Enrollment 24 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov